FOR IMMEDIATE RELEASE

     CARDIMA RECEIVES FDA MARKET CLEARANCE FOR NEW SURGICAL ABLATION SYSTEM

            REVELATION(R) Tx PMA Application Still Pending Before FDA

FREMONT,  Calif. (May 25, 2006) - Cardima, Inc. (OTCBB: CRDM.OB) today announced
that the U.S. Food and Drug  Administration  (FDA) has granted 510(k)  marketing
clearance for the new Cardima  Ablation  System,  which ablates  cardiac  tissue
during heart surgery using radio frequency (RF) energy.  This system is expected
to be used  primarily by surgeons  performing  cardiac  surgery  using  standard
hospital laparoscopic as well as thorascopic techniques.

The  Cardima  Ablation  System  uses three  components:  commercially  available
surgical radio frequency  generators;  the new Cardima  Surgical  Ablation Probe
with a linear array of  multi-electrodes  and adjacent  thermocouples  using the
core  technology  similar  to  the  Company's   REVELATION(R)   series  ablation
micro-catheters; and a novel energy management device called the INTELLITEMP(R),
which  uses a  temperature  feedback  feature  to apply RF  energy  to single or
multiple electrodes on the probe simultaneously. The new surgical ablation probe
includes a specially designed  stabilizer suction device with an illuminated tip
for  better  visibility,  which is clipped to the  electrode  array to  maintain
electrode-tissue contact during hands free ablation.

"I am pleased to see the long  development for the Cardima  Ablation System come
to a successful  completion,"  stated Gabriel Vegh,  chief executive  officer of
Cardima.  "The  new  Cardima  Surgical  Ablation  Probe  has  the  potential  to
effectively  compete with devices on the market designed to replicate the highly
successful  surgical Maze procedure.  We are evaluating  potential marketing and
distribution strategies for the Cardima Ablation System."

Status of REVELATION(R) Tx

Cardima,  Inc.  developed the  REVELATION(R)  Tx linear ablation  micro-catheter
system as a minimally  invasive,  single-use  product  designed to treat  Atrial
Fibrillation (AF).  Cardima submitted the Pre-Market  Approval (PMA) application
to the FDA on September 30, 2002.  On June 26, 2003, we received a  non-approval
letter from the FDA, stating that the efficacy data was not  sufficiently  clear
and supportive for the approval.  On January 20, 2004, we submitted an amendment
to our PMA filing,  in which we provided new  analysis  and an expanded  patient
base. On May 28, 2004,  we received a letter from the FDA,  stating that our PMA
application  was  not  approvable   based  on  the  requirements  of  applicable
regulations.  On June 10,  2005,  we met with the FDA's  Center for  Devices and
Radiological  Health to continue the process  towards  seeking  approval for the
REVELATION(R)  Tx ablation  micro-catheter  for treatment of AF. No  conclusions
were  reached at the end of the  meeting,  but both sides agreed to continue the
dialog. We believe that the data submitted in January 2004 in an amended PMA for
the REVELATION(R) Tx provides sufficient support for safety and effectiveness to
reduce  symptomatic  AF burden  and  improve  the  quality  of life of  patients
suffering  from  self-terminating  but very  uncomfortable  AF within  the least
burdensome guidelines of the FDA.

About Cardima, Inc.

Since our incorporation in November 1992, we have developed, produced and sold a
variety of  micro-catheters  designed for the diagnosis and treatment of the two
most  common  forms  of  cardiac  arrhythmias:   atrial  fibrillation  (AF)  and
ventricular  tachycardia  (VT). Since 2001 our efforts have primarily focused on
developing  differentiated  products that  diagnose and treat AF,  including our
REVELATION(R) Tx micro-catheter  for use in the  Electrophysiology  (EP) market,
and our Surgical Ablation System (SAS) for use in the surgical market.

Except for the historical information contained herein, the matters discussed in
this  press  release  are  forward-looking  statements  that  involve  risks and
uncertainties  that could cause actual results to differ  materially  from those
expressed in or implied by such forward-looking statements.  Potential risks and
uncertainties  include: the uncertainties  associated with the prospects for FDA
approval of our pre-market  approval  application for the  REVELATION(R) Tx; the
prospect for any future  clinical  trials or  regulatory  activities;  the risks
associated  with  the  Apix  loan  facility's  restrictive  covenants,  security
interest,  fee  provisions  and other  terms and  conditions;  the risk that the
Company will not be able to raise  additional  capital in the immediate  term as
needed to  continue  operations  and the risk that we will be unable to secure a
strategic transaction  involving the Surgical Ablation System.  Additional risks
and  uncertainties are set forth in the Company's Annual Report on Form 10-K for
the year ended December 31, 2005, the Company's  Quarterly Report on Form 10-QSB
for the first quarter ended March 31, 2006, and in the Company's  subsequent SEC
filings.  The Company undertakes no obligation to publicly release the result of
any revisions to these  forward-looking  statements  that may be made to reflect
events or circumstances  after the date hereof,  or to reflect the occurrence of
unanticipated events or changes in the Company's plans or expectations.

Contact:
       Cardima, Inc.
       Gabriel Vegh
       510-354-0300
       http://www.cardima.com